Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BMI & Chemo Dose Reduction in Breast Cancer

Clin Breast Cancer; ePub 2016 Jun 22; Raman, Mott, et al

Overweight-obese patients have more frequent chemotherapy dose reductions during neoadjuvant chemotherapy (NAC) for breast cancer when compared to normal weight patients, and this reduction in obese patients was a predictor of not attaining pathologic complete response (pCR). This according to a study of 171 patients with operable breast cancer who received NAC; 112 of whom were overweight-obese. Researchers found:

• Chemotherapy dosing was capped in 2 patients; all others initiated full weight-based treatment.

• Overweight-obese patients required more frequent taxane (44.6% vs 25.4%) and any chemotherapy dose reductions (50.5% vs 33.9%).

• pCR was attained in 29.2% of patients.

• For obese patients, any chemotherapy dose reduction was significantly associated with increased odds of not attaining pCR.

Citation: Raman R, Mott SL, Schroeder M, Phadke S, Masri JE, Thomas A. Impact of body mass index and actual weight based neoadjuvant chemotherapy doses on pathologic complete response in operable breast cancer. [Published online ahead of print June 22, 2016]. Clin Breast Cancer. doi:10.1016/j.clbc.2016.06.008.